◆ NeutralVKTXLLYNVO
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
The Motley Fool·
Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.
Read Full Article at The Motley Fool →